AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
bovnews1d
Viking Therapeutics Inc (VKTX) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
Medindia1d
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
The Motley Fool1d
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
The Globe and Mail5d
Is Viking Therapeutics a Buy on the Dip?
Viking Therapeutics(NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of ...
bovnews6d
What’s Driving Viking Therapeutics Inc (VKTX) Stock’s 9.91% Surge Over the Past Month?
H.C. Wainwright has recently reiterated Viking Therapeutics Inc (VKTX) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on September 11, 2024, JP Morgan had ...
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing partner ...